|
Howard, J.L., Soroko, F.E., & Cooper, B.R. (1981). Empirical behavioral models of
depression, with emphasis on tetrabenazine antagonism. In Enna, S.J., Malick, J.B., & Richelson, E. (Eds.), Antidepressants:
Neurochemical, Behavioral, and Clinical Perspectives (pp. 107-120). New York: Raven Press.
Cooper, B.R., Howard,
J.L., & Soroko, F.E. (1983). Animal models used in prediction of antidepressant effects in man. Journal of Clinical Psychiatry,
44, 63-66.
Howard, J.L., Ferris, R.M., Cooper, B.R., Soroko, F.E., Wang, C.M., & Pollard, G.T. (1989). Models
of depression used in the pharmaceutical industry. In Koob, G.F., Ehlers, C.L., & Kupfers, D.J. (Eds.), Animal Models
of Depression (pp. 187-203). Boston: Birkhauser.
Cooper, B.R., White, H.L., Beek, O., Norton, R.M., Rigdon, G.C.,
Howard, J.L., Kraemer, G.W., & Ferris, R.M. (1992). Overview of the CNS pharmacology of BW 1370U87: A chemically novel,
reversible, selective MAO-A inhibitor with potential to be a new antidepressant drug. Drug Development Research, 25, 181-190.
Beardsley, P.M., Howard, J.L., Shelton, K.L., & Carroll, F.I. (2005) Differential effects of the novel kappa
opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock-stressors vs cocaine-primes and
its antidepressant-like effects in rats. Psychopharmacology, 183, 118-126.
|
